Fibrous dysplasia (FD) of bone may occur solely as a skeletal condition or it may occur in association with extraskeletal manifestations, including growth hormone (GH) excess. Uncertainty exists as to the management of FD involving the optic nerves. In an effort to clarify management, the authors studied a large population of patients. METHODS: One hundred four patients underwent an evaluation that included review of records, endocrine testing, cranial computed tomography, and neuroophthalmological examination. RESULTS: Ninety-one of 104 patients had craniofacial FD; complete records were available for 87 patients (174 nerves). Seventeen percent of the optic nerves were less than 50% encased, 22% were 50 to 99% encased, and 61% were 100% encased. Twelve percent of the nerves that were 100% encased showed evidence of optic neuropathy, but 88% did not. The group with optic neuropathy was not older than the group without. Patients with GH excess were significantly more likely to have nerves that were 100% encased (relative risk, 4.1; 95% confidence interval, 1.5-11.1; P ϭ 0.0017) and to have optic neuropathy (relative risk, 3.8; 95% confidence interval, 2.0-7.1; P ϭ 0.0019). Six prophylactic optic nerve decompressions were performed; in five patients, vision was stable after surgery, and one patient was blind after surgery. Thirteen interventional optic nerve decompression procedures were performed; six of the 13 patients showed some improvement and seven of the 13 showed no improvement or worsened vision. CONCLUSION: The vast majority of optic nerves encased with FD do not exhibit symptoms of optic neuropathy and seem to be stable over time. GH excess is associated with increased risk of nerve encasement and optic neuropathy. Patients with craniofacial FD should be screened for GH excess, and optic nerve decompression should be performed only when there is objective evidence of progressive optic neuropathy.
F
ibrous dysplasia (FD) of bone is a benign skeletal disease in which normal bone is replaced by a benign fibro-osseous tissue (5, 6, 15) . It results from postzygotic activating mutations in the signaling protein G s α (17) . It may appear as a condition of the skeleton only or as part of the McCune-Albright syndrome (MAS), which is clinically defined by FD in combination with either café au lait skin pigmentation and/or at least one of a number of hyperfunctioning endocrinopathies, including precocious puberty, hyperthyroidism, growth hormone (GH) excess, and others (4) . The craniofacial structures and cranial base are involved in many patients, and the optic nerves are usually involved and are often encased circumferentially as they pass through the cranial base (6, 8, 14) . The optimal management of optic nerves circumferentially encased with fibrous dysplastic bone, but without symptoms of optic neuropathy, is controversial (3, 9-11, 13, 16) . Prophylactic decompression is sometimes performed based on the assumption that the risk of future optic neuropathy outweighs the risks of the operation (3, 7, (10) (11) (12) (13) , which include postoperative blindness (3, 7, 13) . The reason for this controversy is the lack of knowledge of the natural history and the risk for blindness in the absence of intervention. It has been pointed out that this controversy could be resolved by data on the natural history of this condition (9) .
We previously demonstrated that significant narrowing of the optic canal with FD was not associated with optic neuropathy (8) and that GH excess may be related to a more severe craniofacial phenotype (1, 8, 19) . Herein, we report on a larger group, with a longer follow-up period, who underwent a uniform and comprehensive evaluation. The goal was to better define the natural history of FD encasing the optic nerve and to identify the pathophysiological mechanisms contributing to the development of optic neuropathy.
PATIENTS AND METHODS
All patients seen at the National Institutes of Health since 1998 with a diagnosis of FD were evaluated. The diagnosis of FD was made based on the results of clinical, radiographical, and histological studies. Craniofacial FD was identified by a combination of nuclear medicine bone scans and computed tomographic (CT) analysis. All patients underwent testing of all relevant endocrine axes. A diagnosis of GH excess was made on the basis of a serum GH level of more than 1.0 ng/ml measured 60 minutes after a standard oral glucose tolerance test. Patients without neuro-ophthalmological examination results were excluded from the relevant sections of analysis. All patients were enrolled in an institutional review boardapproved protocol and gave informed consent.
All patients were evaluated by a single neuro-ophthalmologist (EJF). Testing included best-corrected visual acuity, according to the Early Treatment Diabetic Retinopathy Study scale (20/20 denotes perfect vision); visual fields obtained using the Humphrey Visual Field Analyzer (Humphrey Instruments, San Leandro, CA) using the Swedish Interactive Thresholding Algorithm (SITA) 30-2 program or Goldmann perimetry testing; color vision, with the use of 14 Ishihara color plates; contrast sensitivity testing using the Pelli Robson charts; and results of examination of the fundus. Because there is no definitive test for optic neuropathy, abnormalities suggestive of optic neuropathy resulting from FD were defined as either an abnormal result on the visual field test (such as scotoma or field deficit) or an abnormal result on two of the three other tests performed (visual acuity less than 20/40, correct identification of fewer than 10 of 14 Ishihara color plates, or evidence of optic atrophy on examination of the fundus).
All patients underwent standardized CT imaging of the cranium, on either a 4-or 8-slice helical scanner, using 2.5-to 3.8-mm collimation. The slice reconstruction interval was 1.25 to 1.50 mm. Soft tissue and bone algorithm reconstructions were reviewed by a single neuroradiologist (JAB). The extent of encasement of optic nerves by FD of bone was evaluated in a semiquantitative manner as less than 50, 50 to 99, and 100%. Statistical analyses were performed using InStat software, version 3 (GraphPad Software, Inc., San Diego, CA).
RESULTS
One hundred four patients with FD and MAS were seen at the National Institutes of Health between 1998 and 2005. Of these, 91 (88%) had craniofacial involvement. Demographics for the group are shown in Table 1 . Cranial CT scans were available for 91 patients. Neuro-ophthalmological evaluations were available for 87 (96%) of these 91 patients. In two patients, no examination was performed, and, in two patients, the record of the examination was missing. These four patients were excluded from the relevant analyses. Of the four patients excluded from the analysis because of no neuro-ophthalmological examination, four of the optic nerves were 100% encased and four were less than 50% encased with FD of bone. 
Optic Nerve Encasement
Of the 174 optic nerves, 29 (17%) were less than 50% encased, 38 (22%) were 50 to 99% encased, and 107 were 100% encased with FD of bone (Fig. 1) . The average age of patients with optic nerves 100% encased was 22.5 years (median, 18 yr; range, 3-84 yr), compared with 25.7 years (median, 12.5 yr; range, 6-84 yr) and 29.8 years (median, 31 yr; range, 6-69 yr) for those with a nerve 50 to 99% encased or less than 50% encased, respectively ( Table 1 ). There were no significant age differences between groups with less than 50, 50 to 99, and 100% encasement (P ϭ 0.16, Krushkal-Wallis nonparametric analysis of variance), demonstrating a lack of age-related progression. Patients with GH excess were more likely to have optic nerves 100% encased by FD of bone than those without (relative risk, 4.1; 95% confidence interval, 1.5-11.1; P ϭ 0.0017). All patients with at least one nerve 100% encased had MAS.
Optic Neuropathy
There was no evidence of optic neuropathy in any of the nerves that were either less than 50% or 50 to 99% encased by FD of bone ( Fig. 1 ; Table 2 ). Of the nerves 100% encased by FD of bone, 94 (88%) of 107 exhibited no evidence of optic neuropathy. Optic neuropathy was seen in 13 (12%) of 107 nerves that were 100% encased. Of these, 12 (92%) were surgically decompressed and are discussed below. The remaining one (7%) had only mild neuropathy characterized by a pale fundus and a slow color vision response (10 out of 14 Ishihara color plates correct), which was not noticeable to the patient. This patient's mild optic neuropathy has been stable during 7 years of follow-up. The average age of patients at the time optic neuropathy occurred was 16.3 years (median, 12 yr; range, 5-35 yr), and the average age of those without optic neuropathy was 20.9 years (median, 18 yr; range, 3-84 yr). There was no age difference between the group with and without optic neuropathy (P ϭ 0.3057, two-tailed MannWhitney U test).
Growth Hormone Excess and Aneurysmal Bone Cysts
Seven (54%) out of 13 nerves with optic neuropathy occurred in patients with GH excess ( Fig. 1; Table 2 ). As such, GH excess represented a statistically significant risk factor for the development of optic neuropathy (relative risk, 3 95% confidence interval, 2.0-7.1; P ϭ 0.0019). In two (15%) out of 13 nerves, the development of optic neuropathy was associated with an aneurysmal bone cyst (ABC) that compressed the optic nerves (Fig. 1) , and one nerve (8%) was associated with both GH excess and an ABC. Therefore, in nine (69%) out of 13 nerves, optic neuropathy was associated with either GH excess or an ABC.
Optic Nerve Decompression
Optic nerve decompression was performed on 18 nerves. In the 94 patients without optic neuropathy, there were six prophylactic decompression surgeries (6%). Twelve (92%) of the 13 patients with optic neuropathy underwent 13 decompression surgeries (Fig. 1) . All patients who underwent optic nerve decompression had nerves that were 100% encased. The demographics of the patients who underwent optic neuropathy are shown in Table 3 . The average age of patients who underwent an interventional optic nerve decompression was 14.8 years (median, 12 yr; range, 5-30 yr). The average age at decompression for those who underwent prophylactic procedures was 15.8 years (median, 5.5 yr; range, 5-24 yr), and the average age of patients who did not undergo optic nerve decompression was 24.6 years (median, 19 yr; range, 3-84 yr).
Optic nerve decompressions were performed 13 times on 12 nerves (one for recurrent symptoms). Vision improved as a result of five (38%) of these procedures. One symptomatic nerve had improved vision after the initial optic nerve decompression, but then optic neuropathy developed 10 years later. The symptoms also resolved after the second optic nerve decompression. This patient had associated GH excess. Slight improvement was seen in one (8%), no improvement was reported in four (31%), and vision loss was reported in two (15%) of 13 procedures ( Table 4) .
Six prophylactic optic nerve decompressions were performed on six nerves that were 100% encased, but in which there were no symptoms of optic neuropathy ( Fig. 1; Table 4 ). Five (83%) out of six of these nerves were intact after surgery with no change in vision. However, one (17%) of the six sustained intraoperative injury resulting in blindness.
DISCUSSION
The proper handling of optic nerves encased by FD without symptoms of neuropathy has long been controversial. Many authors recommend prophylactic decompression based on the assumption that the disease is progressive and that optic neuropathy is an inevitable complication. This recommendation assumes that the risk of prophylactic decompression-which includes blindness-is less than the risks associated with no treatment for asymptomatic nerves. In a previous study of 67 nerves, we demonstrated that narrowing of the optic canal alone is not necessarily associated with visual loss (8) . In this study, we extend these findings to a larger cohort and demonstrate that, in most patients, vision loss is associated with either GH excess or an ABC.
In 93% of the 174 nerves, there was no evidence of optic neuropathy, and there was no optic neuropathy in nerves less than 100% encased. Of the 107 optic nerves that were 100% encased, 88% exhibited no evidence of optic neuropathy. There was no difference in age between groups with less than 50, 50 to 99, and 100% encasement, and patients with optic neuropathy were not older than those without optic neuropathy. These data support the conclusion that encasement does not progress with age and that increasing age does not necessarily bring with it the likelihood of optic neuropathy and blindness. Thus, prophylactic decompression should not be performed on patients without symptoms merely as an effort to prevent possible future optic neuropathy.
Two associations suggested the pathophysiological mechanism of optic neuropathy, namely GH excess and the presence of an ABC. Sixty-nine percent of the patients with optic neuropathy had either GH excess or an ABC of the cranial base. GH (and/or its trophic hormone insulin-like growth factor I) seems to promote growth and expansion of craniofacial FD. Patients with craniofacial FD and GH excess are more prone to macrocephaly, and there is a significant linear correlation between serum GH levels and head circumference in patients with craniofacial FD and GH excess (2) . Furthermore, there is evidence that optic nerve stretching resulting from bone expansion may be the mechanism of vision loss in some patients with GH excess and craniofacial FD (8) . This is significant because GH excess is a potentially treatable disease (1, 18 ). Yet, early in the course of MAS, when intervention is perhaps most important to prevent long-term morbidity, GH excess is usually not clinically evident. Its presentation may be as subtle as normal stature in a young adult who experienced precocious puberty and should have short stature as a consequence of early growth plate closure. Therefore, referral for specific testing for GH excess is essential. This suggests that, in the absence of the comorbidities of GH excess, an ABC, or both, the baseline rate of optic neuropathy in craniofacial FD is quite low. With such a low rate of optic neuropathy, the risk of injury to the optic nerve during prophylactic optic nerve decompression becomes an even greater consideration. Fifteen (83%) out of 18 patients who underwent optic nerve decompression still had 100% encasement of the optic nerve on postoperative cranial CT scans ( Fig. 2; Table 4 ). It is not known whether this was the result of incomplete decompression or regrowth. Despite persistent (or recurrent) 100% encasement in these patients, only two out of 15 patients, both of whom had GH excess, experienced symptoms of optic neuropathy. This suggests that, even if FD of bone is removed from around the optic nerve, it is likely to recur, further questioning the prudence of decompression in the absence of symptoms.
It is possible that the low rate of optic neuropathy in the group is the result of referral bias because ours is a medically based treatment group. Against this argument is the fact that, as a group, this was a more severely affected group of patients with FD. The ratio of MAS to polyostotic FD to monostotic FD was 91:8:1, the relative inverse of a random group of patients with FD (6).
CONCLUSION
Complete encasement of the optic nerve in FD of the cranial base is common, but is not commonly associated with optic neuropathy. There does not seem to be an age-related progression to optic neuropathy in patients in whom the optic nerve is encased, suggesting that, in most cases, the condition is stable. The vast majority of cases of optic neuropathy are seen in patients with either GH excess, an ABC, or both. Risk factors for the development of ABCs are not known, but GH excess, which is seen in approximately 20% of the patients with MAS, is relatively easy to diagnose and is treatable. Patients with craniofacial FD should be screened for GH excess, and prophylactic decompression should be reserved for patients with objective signs of optic neuropathy. 
FIGURE 2. Preoperative (A-D) and postoperative (E-H)CT scans obtained from a 12-year-old girl with MAS and GH excess (Patient 7,

